EGFR mutations represent the second most common oncogenic driver event in lung cancer and accounts for ~15–20% of lung adenocarcinoma cases, while EGFR mutations are rare in other NSCLC subtypes [38,39]. The gene discussed is EGFR; the disease is lung cancer.